Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
328 Marcovecchio, M
To view a copy of this licence, visit About this article Cite this article Dumbill, R., Knight, S., Hunter, J
Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism
Additional considerations include: Dietary quality changes during weight loss programmes Increased urinary magnesium excretion in poorly controlled diabetes (though GLP-1 therapy typically improves glycaemic control) Concurrent medications that may affect magnesium status, such as proton pump inhibitors or diuretics It is important to note that routine magnesium monitoring is not currently recommended in NICE guidance (NG28) for patients on GLP-1 therapy
US$ 21.43
US$ 25.60
US$ 27.53
US$ 29.27
US$ 23.93
